Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
The last day of operation for Hertfordshire and West Essex ICB was 31 March 2026. The information on this website has not been updated since 31 March 2026. The legacy policies, prescribing recommendations and pathways can be accessed on this website. Find out more
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Acetylcysteine 600mg capsules | Mucolytic | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Acetylcysteine 600mg effervescent tablets [special] | Mucolytic | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Acetylcysteine 600mg S/F effervescent tablets | Mucolytic | Green | Decision document | Hertfordshire and West Essex ICB |
| Acetylcysteine 600mg tablets | Mucolytic | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Alimemazine | All indications, execluding sedation in paediatrics prior to diagnostic scans | Red | n/a | Hertfordshire and West Essex ICB |
| Amikacin | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Anaphylaxis Auto Adrenaline Injector | Anaphylaxis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | Inhaled corticosteroids (ICS) choices | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | MART - Asthma Management in over 12 years | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | Adults 18 years and over | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | SABA Q&A ECF 25-26 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Asthma | Children 5 to 19 years | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | Step down guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Azithromycin | COPD | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Aztreonam lysine | Cystic fibrosis chronic pseudomonas aeruginosa (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Benralizumab | Severe eosinophilic asthma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bibecfo (ICS - beclometasone / LABA - formoterol) | Asthma | Green | Decision document | Hertfordshire and West Essex ICB |
| Breathlessness | Non-Acute | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Bronchiectasis in Adults | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Carbocisteine 250mg/5ml oral solution | Mucolytic | Green | Decision document | Hertfordshire and West Essex ICB |
| Carbocisteine 250mg/5ml oral solution S/F | Mucolytic | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Carbocisteine 375mg capsules | Mucolytic | Green | Decision document | Hertfordshire and West Essex ICB |
| Carbocisteine 750mg capsules | Mucolytic | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Carbocisteine 750mg capsules dose optimisation switch patient letter | Green | Patient information | Hertfordshire and West Essex ICB | |
| Carbocisteine 750mg/10ml oral sachets S/F | Mucolytic | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Carbocisteine 750mg/10ml oral solution S/F | Mucolytic | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Colistimethate sodium (Colobreathe) | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Community LRTI Pneumonia Intravenous Antibiotic pathway for Housebound Care Home patients Pathway | n/a | Clinical pathways | East and North Hertfordshire | |
| COPD | COPD | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| COPD Pathway | n/a | Clinical pathways | East and North Hertfordshire | |
| COPD treatment guidelines | COPD | n/a | Decision document | Hertfordshire and West Essex ICB |
| Cough in Adults | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| COVID-19 treatments: Information for care homes | COVID 19 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| COVID-19 treatments: Information for community pharmacists | COVID 19 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Cytisine (cytisinicline) | Smoking cessation | Red | n/a | Hertfordshire and West Essex ICB |
| Dornase alfa | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Gefapixant | Refractory or unexplained chronic cough | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Inhaled corticosteroids | Asthma COPD - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Inhaler - environmentally friendly | Asthma COPD | n/a | Patient information | Hertfordshire and West Essex ICB |
| Inhaler reliever | Asthma | n/a | Patient information | Hertfordshire and West Essex ICB |
| Isavuconazole | Antifungal (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Ivacaftor | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Kelhale inhaler | Asthma | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Mannitol dry powder for inhalation | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Mechanical Insufflation-Exsufflation (MI-E) Devices / CoughAssist | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Palforzia | Peanut allergy (Specialist allergy centre) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Pirfenidone | Idiopathic pulmonary fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Pulmonary Rehabilitation | n/a | Clinical pathways | East and North Hertfordshire | |
| Quick Reference Guide – Optimising Prescribing in Respiratory | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
| Referral and Surgery for Snoring, Sleep Disordered Breathing and Obstructive Sleep Apnoea | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Remdesivir | COVID‑19 | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Respiratory Conditions Referral Pathway | n/a | n/a | South and West Hertfordshire | |
| Roflumilast | COPD | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Salamol - letter | Asthma COPD | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Salamol - poster | Asthma COPD | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Sildenafil (20mg tablets) | Pulmonary arterial hypertension (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
| Snoring and Sleep Apnoea Management in Adults | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Spacer | Asthma COPD | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Tixagevimab plus cilgavimab | COVID‑19 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tobramycin (TOBI Podhaler) | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Trimbow (ICS - beclometasone / LABA - formoterol / LAMA - glycopyrronium) | Asthma | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Varenicline | Smoking cessation | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |